Welcome to our dedicated page for Sanofi FR news (Ticker: SNY), a resource for investors and traders seeking the latest updates and insights on Sanofi FR stock.
Sanofi American Depositary Shares (NASDAQ: SNY) represent an R&D driven, AI-powered biopharma company that regularly issues news on its medicines, vaccines, pipeline programs, and strategic initiatives. Company communications describe a focus on immunology, autoimmune diseases, rare diseases, diabetes, respiratory conditions, and infectious disease prevention, which generates a steady flow of clinically and commercially relevant updates.
News about Sanofi often covers clinical trial milestones, regulatory decisions, and collaborations. Recent examples include collaborations with Dren Bio on next-generation B-cell depletion therapies for autoimmune disease, a collaboration and license agreement with EVOQ Therapeutics around NanoDisc technology for autoimmune conditions, and a partnership with Revvity to support development and validation of a type 1 diabetes autoantibody assay for early detection. Sanofi also reports on RSV prevention with BEYFORTUS, COPD care initiatives with Viz.ai and Regeneron, and progress in alpha-1 antitrypsin deficiency emphysema.
Investors and healthcare observers will also find corporate and strategic news, such as Sanofi’s intention to invest at least $20 billion in the United States through 2030, the opening of new flagship offices in Morristown, New Jersey, and the planned acquisition of Blueprint Medicines to expand its rare immunological disease portfolio. Additional releases highlight community-focused programs like the Healthy Futures Solution Fund and the expansion of the Insulins Valyou Savings Program in the US.
This SNY news page aggregates these announcements, providing a single place to follow Sanofi’s clinical data readouts, regulatory updates, partnerships, acquisitions, access and affordability initiatives, and other developments that shape the company’s role in global healthcare.
Summary not available.
Summary not available.
Sanofi has launched AVAXIM® Junior in the UK, an inactive hepatitis A vaccine aimed at children aged 12 months to 15 years. The vaccination entails two doses administered intramuscularly, ideally spaced between 6 to 36 months but can extend to 7 years. The launch is supported by data from 20 clinical studies across 14 countries, involving more than 6,200 children, demonstrating over 95% efficacy in inducing a protective antibody response within two weeks. AVAXIM Junior addresses the prevalence of hepatitis A, a common travel-related disease, providing parents with reassurance when traveling to high-risk areas. Side effects typically include soreness at the injection site and general malaise. Sanofi, listed on Euronext and NASDAQ as SNY, aims to enhance global health through innovative treatments and vaccine options.
Sanofi and BARDA celebrated the groundbreaking of a new formulation and filling facility in Swiftwater, Pennsylvania, on April 4, 2023. This state-of-the-art facility, supported by federal funds, aims to enhance the manufacturing of pandemic influenza vaccines. It will include cutting-edge technology for syringe and vial filling, contributing to Sanofi's commitment to pandemic preparedness. The project complements a contract awarded in December 2019 to boost domestic vaccine production capabilities. Sanofi plans to utilize advanced recombinant technology, expanding its capacity to deliver effective vaccines during pandemics.
Sanofi has introduced the Sanofi NextGen Scholarship at the 53rd Annual Meeting of the World Economic Forum in Davos. This global initiative aims to support students from underrepresented communities pursuing careers in healthcare. Starting in Brazil, France, Japan, the UK, and the U.S., the program will award funding for up to 100 selected students annually, covering tuition and living costs. The scholarship also includes mentorship and internship opportunities. Sanofi's initiative follows a global survey revealing significant trust issues in healthcare among underrepresented populations, highlighting a need for greater diversity in healthcare roles.
Regeneron Pharmaceuticals and Sanofi announced that a Phase 3 trial of Dupixent (dupilumab) 300 mg weekly for treating eosinophilic esophagitis (EoE) showed significant improvements in patient histology and symptoms compared to placebo. Improvements were sustained for up to one year in patients aged 12 and older. Dupixent is the first U.S. approved targeted treatment for EoE. The FDA approved Dupixent in May 2022, and the EMA has given a positive opinion for its use in Europe. Safety results matched Dupixent's known profile, suggesting a favorable risk-benefit ratio.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has expanded its collaboration with Sanofi (NASDAQ: SNY) by granting an exclusive license for its B7H3 ANKETTM program. Sanofi will be accountable for all development and commercialization activities. Innate will receive an upfront payment of €25 million and up to €1.35 billion in potential milestones, along with royalties from net sales. This partnership continues the 2016 collaboration focused on NK cell engagers, enhancing Innate's cancer treatment portfolio and Sanofi's oncology strategy.
Regeneron Pharmaceuticals and Sanofi announced that the European Medicines Agency's Committee has recommended Dupixent for approval to treat adolescents and adults aged 12 and over with eosinophilic esophagitis (EoE). This would make Dupixent the first targeted treatment for EoE in the EU, following its U.S. approval in May 2022. The positive recommendation is based on pivotal trial data showing significant improvements in patients' ability to swallow and histological remission. The European Commission will make a final decision soon.
Regeneron Pharmaceuticals and Sanofi announced that the European Commission approved Dupixent (dupilumab) for treating adults with moderate-to-severe prurigo nodularis, marking it the first targeted medicine for this condition in Europe. Clinical trials showed that 60% of Dupixent patients experienced significant itch reduction at 24 weeks, compared to 18% for placebo. The drug also improved skin lesions and overall quality of life. Approximately 70,000 adults in Europe are affected by this chronic skin disease, underscoring the need for effective treatment options.
Regeneron Pharmaceuticals and Sanofi announced a positive opinion from the European Medicines Agency (EMA) recommending Dupixent (dupilumab) for treating adults with moderate-to-severe prurigo nodularis. If approved, Dupixent will be the first targeted medicine for this condition in the EU. Supported by two pivotal Phase 3 trials, the drug significantly improved itch, skin lesions, and health-related quality of life. Dupixent is already FDA-approved for the same indication in the U.S. The final decision from the European Commission is anticipated shortly.